Abstract:Technology in Cancer Research &Treatment, Volume 23, Issue , January-December 2024. Purpose: This study aimed to analyze the efficacy and safety of neoadjuvant and adjuvant immunotherapies for non-small cell lung cancer (NSCLC). Methods: Electronic literature searches were conducted in PubMed, OVID, Web of SCI, Embase, Cochrane Library, and the Chinese National Knowledge Infrastructure databases. The deadline for literature update and retrieval is February 16, 2024. Studies presented at meetings were also screened. Randomized controlled trials (RCTs) and single-arm trials were included, and the data were extracted according to the inclusion and exclusion criteria. Data analysis was performed using Stata (16.0) software. Results: A total of 5850 patients in 11 RCTs and 6 single-arm trial studies involving neoadjuvant and/or adjuvant immune checkpoint inhibitor (ICI)-based therapies were included. Regarding neoadjuvant therapy, the overall complication rate after surgery reached 35% (95% CI, 0.21-0.49). Higher rates of pathological complete response (OR = 7.83; 95% CI, 5.95-10.31; P < .001) and major pathological response (OR = 5.13; 95% CI, 3.56-7.40; P < .001) were found in the resectable NSCLC patients who received neoadjuvant therapy with ICIs combined with chemotherapy compared with patients treated with chemotherapy alone. Of note, compared with chemotherapy, neoadjuvant ICIs combined with chemotherapy significantly improved the overall survival (OS) (HR = 0.65; 95% CI, 0.52-0.82; P < .001) and event-free survival (EFS) (HR = 0.59; 95% CI, 0.52-0.67; P < .001) in patients with resectable NSCLC. Regarding adjuvant therapy, a lower risk of disease progression or death (HR = 0.78; 95% CI, 0.69-0.90; P < .001) was found in the adjuvant ICI group compared with the adjuvant chemotherapy-alone group. In terms of safety, perioperative immunotherapy combined with chemotherapy did not increase toxicity compared with chemotherapy alone. Conclusion: In patients with resectable NSCLC, perioperative immunotherapy was safe and efficacious. Perioperative immunotherapy combined with chemotherapy improved the pathologic response and EFS/DFS/OS over chemotherapy alone without increasing toxicity.

Emerging Evidence from Landmark Clinical Trials on Perioperative Immunotherapy in Resectable Non-Small Cell Lung Cancer

Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review

[Perioperative Immunotherapy for Resectable Non-Small Cell Lung Cancer: Current Evidence and New Standard of Care]

The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer

Perioperative immunotherapy in nonsmall cell lung cancer

Perioperative immunotherapy for non-small cell lung cancer: practical application of emerging data and new challenges

Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer

Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Expert Consensus on Perioperative Immunotherapy for Local Advanced Non-Small Cell Lung Cancer

[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].

Perioperative Immunotherapy for Node-Negative Non-Small Cell Lung Cancer – Current Evidence and Future Directions

Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Perioperative systemic therapies for non-small-cell lung cancer: Recent advances and future perspectives

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Perioperative immunotherapy for nonsmall cell lung cancer

The Value of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Pool- and Meta-Analysis

The Earlier, the Better? A Review of Neoadjuvant Immunotherapy in Resectable Non‐small‐cell Lung Cancer

The role of immunotherapy in early-stage and metastatic NSCLC

Clinical Challenges in Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.